Research ExplorerPublicationsPrognostic use of soluble fms-like tyrosine kinase-1 and pla...

Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease

Standard

Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease. / Sinning, Christoph; Schnabel, Renate B; Zeller, Tanja; Seiffert, Moritz; Rupprecht, Hans J; Lackner, Karl J; Blankenberg, Stefan; Bickel, Christoph; Westermann, Dirk.

In: BIOMARK MED, Vol. 10, No. 1, 2016, p. 95-106.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Sinning, C, Schnabel, RB, Zeller, T, Seiffert, M, Rupprecht, HJ, Lackner, KJ, Blankenberg, S, Bickel, C & Westermann, D 2016, 'Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease', BIOMARK MED, vol. 10, no. 1, pp. 95-106. https://doi.org/10.2217/bmm.15.111

APA

Sinning, C., Schnabel, R. B., Zeller, T., Seiffert, M., Rupprecht, H. J., Lackner, K. J., Blankenberg, S., Bickel, C., & Westermann, D. (2016). Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease. BIOMARK MED, 10(1), 95-106. https://doi.org/10.2217/bmm.15.111

Vancouver

Sinning C, Schnabel RB, Zeller T, Seiffert M, Rupprecht HJ, Lackner KJ et al. Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease. BIOMARK MED. 2016;10(1):95-106. https://doi.org/10.2217/bmm.15.111

Bibtex

@article{cf43cad755ca4c258b40cdf957b8e2d3,
title = "Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease",
abstract = "BACKGROUND: Intention of the study is to assess the cardiovascular mortality of patients with coronary artery disease (CAD) with the biomarkers of angiogenesis PlGF and its endogenous inhibitor sFlt-1.METHODS: The cohort included n = 1848 patients with CAD and 282 subjects without CAD. In 85 patients cardiovascular mortality, as combination of fatal myocardial infarction or any cardiac death, during a median follow-up duration of 3.9 years was reported.RESULTS: In Kaplan-Meier curve analysis PlGF in rising thirds was not predictive regarding outcome (p = 0.54), the same was shown for sFlt-1 (p = 0.44). Cox regression for the fully adjusted model provided a hazard ratio (HR) of 0.8 (p = 0.18) for PlGF and for sFlt-1 a HR = 1.0 (p = 0.8).CONCLUSION: Our results point out that these biomarkers reflecting angiogenesis might not be suited to establish prognosis in CAD.",
keywords = "Coronary Artery Disease/blood, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Natriuretic Peptide, Brain/blood, Peptide Fragments/blood, Placenta Growth Factor, Pregnancy Proteins/blood, Prognosis, Vascular Endothelial Growth Factor Receptor-1/blood",
author = "Christoph Sinning and Schnabel, {Renate B} and Tanja Zeller and Moritz Seiffert and Rupprecht, {Hans J} and Lackner, {Karl J} and Stefan Blankenberg and Christoph Bickel and Dirk Westermann",
year = "2016",
doi = "10.2217/bmm.15.111",
language = "English",
volume = "10",
pages = "95--106",
journal = "BIOMARK MED",
issn = "1752-0363",
publisher = "Future Medicine Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease

AU - Sinning, Christoph

AU - Schnabel, Renate B

AU - Zeller, Tanja

AU - Seiffert, Moritz

AU - Rupprecht, Hans J

AU - Lackner, Karl J

AU - Blankenberg, Stefan

AU - Bickel, Christoph

AU - Westermann, Dirk

PY - 2016

Y1 - 2016

N2 - BACKGROUND: Intention of the study is to assess the cardiovascular mortality of patients with coronary artery disease (CAD) with the biomarkers of angiogenesis PlGF and its endogenous inhibitor sFlt-1.METHODS: The cohort included n = 1848 patients with CAD and 282 subjects without CAD. In 85 patients cardiovascular mortality, as combination of fatal myocardial infarction or any cardiac death, during a median follow-up duration of 3.9 years was reported.RESULTS: In Kaplan-Meier curve analysis PlGF in rising thirds was not predictive regarding outcome (p = 0.54), the same was shown for sFlt-1 (p = 0.44). Cox regression for the fully adjusted model provided a hazard ratio (HR) of 0.8 (p = 0.18) for PlGF and for sFlt-1 a HR = 1.0 (p = 0.8).CONCLUSION: Our results point out that these biomarkers reflecting angiogenesis might not be suited to establish prognosis in CAD.

AB - BACKGROUND: Intention of the study is to assess the cardiovascular mortality of patients with coronary artery disease (CAD) with the biomarkers of angiogenesis PlGF and its endogenous inhibitor sFlt-1.METHODS: The cohort included n = 1848 patients with CAD and 282 subjects without CAD. In 85 patients cardiovascular mortality, as combination of fatal myocardial infarction or any cardiac death, during a median follow-up duration of 3.9 years was reported.RESULTS: In Kaplan-Meier curve analysis PlGF in rising thirds was not predictive regarding outcome (p = 0.54), the same was shown for sFlt-1 (p = 0.44). Cox regression for the fully adjusted model provided a hazard ratio (HR) of 0.8 (p = 0.18) for PlGF and for sFlt-1 a HR = 1.0 (p = 0.8).CONCLUSION: Our results point out that these biomarkers reflecting angiogenesis might not be suited to establish prognosis in CAD.

KW - Coronary Artery Disease/blood

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Natriuretic Peptide, Brain/blood

KW - Peptide Fragments/blood

KW - Placenta Growth Factor

KW - Pregnancy Proteins/blood

KW - Prognosis

KW - Vascular Endothelial Growth Factor Receptor-1/blood

U2 - 10.2217/bmm.15.111

DO - 10.2217/bmm.15.111

M3 - SCORING: Journal article

C2 - 26642248

VL - 10

SP - 95

EP - 106

JO - BIOMARK MED

JF - BIOMARK MED

SN - 1752-0363

IS - 1

ER -